1. Introduction {#sec1-microorganisms-08-00375}
===============

*Acinetobacter* (A.) *baumannii* is a ubiquitous, Gram-negative, non-motile bacterium associated with hospital-acquired infection globally. It has been classified among the most dangerous multiple drug-resistant (MDR) pathogens worldwide. It has been listed in the "priority 1: critical" pathogens list of the World Health Organization (WHO). The pathogen was found in humans, animals, foods and the environment. *A. baumannii* is associated with severe infection, high mortality rates and massive economic loss \[[@B1-microorganisms-08-00375]\]. Since the late 20th century, this bacterium emerged as a major cause of healthcare-associated infection in critically ill patients causing bloodstream infections, ventilator-associated pneumonia, meningitis, endocarditis, wound infection, urinary tract infections, skin and soft tissues infections \[[@B2-microorganisms-08-00375]\]. Mortality rates can reach 35% in ventilator-associated pneumonia and bloodstream infections \[[@B3-microorganisms-08-00375]\]. Members of the genus *Acinetobacter* are usually environmental bacteria. For unclear reasons, *A. baumannii* emerged as an opportunistic nosocomial pathogen. It has established niches for survival in hospitals as well as in primary animal production systems and the environment \[[@B4-microorganisms-08-00375]\]. The main vital factors contributing to the extravagant dissemination of *A. baumannii* in hospitals are a large variety of potential sources of entry, environmental resilience and its ability to develop resistance to the majority of antibiotics, particularly the ability to acquire resistance to carbapenems \[[@B1-microorganisms-08-00375],[@B5-microorganisms-08-00375]\]. *A. baumannii* becomes resistant via reducing membrane permeability, increasing efflux pump activity and production of a wide variety of β-lactamases. It is also able to acquire resistance via mutations and through horizontal gene transfer \[[@B6-microorganisms-08-00375]\]. *A. baumannii* exhibits high genetic plasticity, which allows the accumulation of the acquired resistance determinants \[[@B7-microorganisms-08-00375]\]. Resistance in this pathogen is frequently associated with mobile genetic elements (MGEs) that are transferable between bacteria, thus enabling the rapid dissemination of resistance genes between bacteria of different species and creating a reservoir of antimicrobial-resistance (AMR) genes \[[@B7-microorganisms-08-00375]\].

For several years, the prevalence of infection with MDR *A. baumannii* has been increasing dramatically in the European countries that is, from 15.4% in 2004 to 48.5% in 2014 \[[@B8-microorganisms-08-00375]\]. In the late 20th century, *A. baumannii* has emerged as a significant nosocomial pathogen in Germany \[[@B9-microorganisms-08-00375],[@B10-microorganisms-08-00375],[@B11-microorganisms-08-00375]\]. Numerous nosocomial outbreaks were reported among inpatients and preterm infants with a considerable mortality rate of up to 24% after bacteremia in intensive care units at a large teaching hospital of Cologne \[[@B12-microorganisms-08-00375]\]. Since 2000, the number of reported cases and hospital outbreaks was increasing continuously in most German states \[[@B13-microorganisms-08-00375],[@B14-microorganisms-08-00375],[@B15-microorganisms-08-00375],[@B16-microorganisms-08-00375],[@B17-microorganisms-08-00375]\]. Isolates with resistance to all β-lactams, including carbapenems \[[@B18-microorganisms-08-00375]\] and last resort antimicrobial agents such as colistin and tigecycline \[[@B19-microorganisms-08-00375]\], were reported nationwide and have become a significant cause of worry of the healthcare system. Several studies on *A. baumannii* have been published from different German states but a systematic review on its spatial and temporal distribution is not yet available. Thus, the current report aims at providing a comprehensive, evidence-based assessment of the literature published from 2000-2018 on *A. baumannii* in Germany.

2. Materials and Methods {#sec2-microorganisms-08-00375}
========================

2.1. Data Sources and Search Strategy {#sec2dot1-microorganisms-08-00375}
-------------------------------------

A comprehensive search in PubMed, Web of Science, Scopus and the catalogue of the German National Library was performed for articles that include the search terms "*Acinetobacter baumannii*" and "Germany" in their title and abstract. All national and international studies discussing *A. baumannii* in Germany published in both English and German language were collected. References cited within these papers were checked to find additional relevant information.

2.2. Selection Criteria and Data Extraction {#sec2dot2-microorganisms-08-00375}
-------------------------------------------

Studies discussing isolation, epidemiology and antimicrobial resistance of *A. baumannii* from 2000 through 2018 were included. Review articles, congress abstracts, case reports, letters, commentaries and editorials were included. Abstract analysis for each publication was done and, if selected, the full text was carefully analyzed. The following keywords were used---*Acinetobacter baumannii* + Germany + human + antimicrobial resistance. Articles describing other *Acinetobacter* spp., *A. baumannii* in non-human sources, novel diagnostics, development of PCR and studies published before the year 2000 were excluded. For each study, following information was extracted from the full text---first author, year of publication, sampling date, location of sampling (city and state), study population, type and source of samples, number of strains and cases, type of study, resistance profiles of the recovered strains including phenotypic testing and detection of resistance genes. If available, the sequence and clonal type of strains were included.

2.3. Data Acquisition and Analysis {#sec2dot3-microorganisms-08-00375}
----------------------------------

Overall, a total of 216 potentially relevant articles \[PubMed (*n* = 114), Scopus (*n* = 69) and Web of Science (*n* = 33)\] were identified. Sixty-one articles were selected for screening and forty-four studies were included in the review ([Figure 1](#microorganisms-08-00375-f001){ref-type="fig"}: PRISMA diagram). The information was categorized starting with the latest one.

2.4. Relative Research Interest {#sec2dot4-microorganisms-08-00375}
-------------------------------

The number of publications that are available on PubMed for each year was extracted and the relative research interest was calculated \[[@B20-microorganisms-08-00375]\]. It is defined as the quotient of specific articles divided by all articles in this year to consider the overall publication growth per year.

3. Results {#sec3-microorganisms-08-00375}
==========

3.1. Data Analysis {#sec3dot1-microorganisms-08-00375}
------------------

Case reports represented the majority of the published articles (*n* = 14), followed by outbreak reports (*n* = 7) and evaluation of antibiotic activity (*n* = 6). The remaining studies were surveillance studies, routine microbiological examination and descriptive data analysis. Thirty-seven articles were published in English and seven in German \[[@B15-microorganisms-08-00375],[@B16-microorganisms-08-00375],[@B17-microorganisms-08-00375],[@B18-microorganisms-08-00375],[@B19-microorganisms-08-00375],[@B20-microorganisms-08-00375],[@B21-microorganisms-08-00375]\]. The sampling date was not reported in 15 studies, while the geographical location of samples was ignored in three studies. Lost information was categorized as "non-determined" and referred to as 'ND' in the tables. *A. baumannii* was most often isolated from the bloodstream, wound infections and respiratory and urinary tract infections as well as from skin and rectal swabs. In outbreak investigations it was also isolated from the patient's environment, medical devices, patient's associated belongings, room equipment, infusion pumps and oxygen masks \[[@B20-microorganisms-08-00375],[@B22-microorganisms-08-00375]\]. In the catalogue of the German National Library, 148 doctoral theses containing the word *Acinetobacter* in their titles were identified. Twenty-one of these were published between 2000--2018. Only nine dissertations with emphasis on isolation, molecular and functional typing, distribution and genetic composition of AMR determinants were found (data are not shown). Three of these were done in Bonn, three in Cologne and one each in Berlin, Freiburg and Frankfurt am Main representing the main centres of *A. baumannii* research.

3.2. Temporal Distribution of the Analyzed Studies {#sec3dot2-microorganisms-08-00375}
--------------------------------------------------

The emergence of MDR in *A. baumannii* has been steadily increasing over time and the number of published articles reflects this fact. The relative research interest has been growing after 2013. The year 2010 was super crucial for the research on *A. baumannii* in Germany. PubMed analysis using the search term '*A. baumannii* in Germany' showed a gradual increase in the number of published studies over time with the highest number of annual articles in 2018 ([Figure 2](#microorganisms-08-00375-f002){ref-type="fig"}). Finally, 44 articles were analyzed. Approximately two thirds of studies (*n* = 32) were published in or after 2010, of them 13 articles have been published in the years 2016--2018 ([Table 1](#microorganisms-08-00375-t001){ref-type="table"}).

3.3. Spatial Distribution of the Analyzed Studies Based on Geographical Location of Sampling {#sec3dot3-microorganisms-08-00375}
--------------------------------------------------------------------------------------------

Most of the published articles are regional studies. Only six studies included samples throughout Germany but without the exact geographical origin of samples. North Rhine-Westphalia, Hesse and Baden-Wuerttemberg contributed eleven, eight and five studies, respectively, followed by Bavaria (four studies), Saxony (three studies) and Berlin and Schleswig-Holstein (two studies each). From Thuringia, Hamburg, Lower Saxony, Saxony-Anhalt, Rhineland-Palatinate and Mecklenburg-Vorpommern, only one study was accessible. Brandenburg, Bremen and Saarland are not present at all. Cologne, the largest city of North Rhine-Westphalia, was the most represented city and was mentioned in six studies. Frankfurt am Main, the largest city of Hesse, was mentioned in five studies. Both cities are centers of *A. baumannii* research. Munich, the largest city of Bavaria, contributed three studies. Leipzig, one of the biggest cities of Saxony, Tuebingen and Freiburg, two cities in Baden-Württemberg, were study areas for two studies each ([Table 1](#microorganisms-08-00375-t001){ref-type="table"}).

3.4. Official Data Concerning the Infection and Epidemiology of Acinetobacter in Germany {#sec3dot4-microorganisms-08-00375}
----------------------------------------------------------------------------------------

Within the framework of the Infection Protection Act in Germany, the Robert Koch Institute (RKI) is responsible for collecting data on notifiable diseases. The number of nosocomial outbreaks and the number of cases in each outbreak, as well as the number of deaths were recorded for 2010 onwards \[[@B59-microorganisms-08-00375]\]. As shown in [Table 2](#microorganisms-08-00375-t002){ref-type="table"}, no information has been documented in 2010 and 2011 and for the years 2012, 2013 and 2016 the highest numbers of nosocomial outbreaks were reported. The annual statistics on reportable diseases of Germany reported 794 and 784 *Acinetobacter* infections or colonization in 2017 and 2018, with an incidence of 1.0 and 0.9, respectively. North Rhine-Westphalia reported the highest numbers of *Acinetobacter* infections or colonizations with 405 notifications, followed by Bavaria (*n* = 205), Hesse (*n* = 200) and Berlin (*n* = 196) \[[@B60-microorganisms-08-00375]\]. In contrast, the lowest incidences were reported for the federal states of Bremen (*n* = 6) and Saarland (*n* = 5). It has to be taken into consideration that the numbers mentioned in the RKI statistics do not represent the total number of infections in Germany because only the carbapenem-non-susceptible isolates are reported to the RKI and species of *Acinetobacter* are not differentiated.

3.5. Identification of A. baumannii and Antibiotic Susceptibility Testing (AST) {#sec3dot5-microorganisms-08-00375}
-------------------------------------------------------------------------------

Identification of *A. baumannii* has been done mostly by the VITEK-2 system, MALDI-TOF \[[@B18-microorganisms-08-00375],[@B26-microorganisms-08-00375]\] and detection of the intrinsic *bla*OXA-51-like gene \[[@B30-microorganisms-08-00375]\]. Phenotypic antibiotic sensitivity testing (AST) was performed with the VITEK-2 platform, E-test \[[@B28-microorganisms-08-00375]\], disk diffusion method \[[@B24-microorganisms-08-00375]\], antibiotic gradient test and micro-broth dilution using Micronaut-S system \[[@B22-microorganisms-08-00375]\]. The National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method and the respective breakpoints were used until 2006 \[[@B52-microorganisms-08-00375]\]. The broth dilution test was performed following the guidelines of the German Institute for Standardization (DIN) in 2010 \[[@B46-microorganisms-08-00375]\] and 2013 \[[@B39-microorganisms-08-00375]\]. The phenotypic detection of resistance in most of the published studies was performed following the Clinical and Laboratory Standards Institute (CLSI) recommendations and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). No breakpoint for tigecycline is approved by EUCAST \[[@B49-microorganisms-08-00375],[@B50-microorganisms-08-00375]\]. Thus, the breakpoint of EUCAST for *Enterobacteriaceae* has been used \[[@B16-microorganisms-08-00375]\].

3.6. Resistance Development of A. baumannii {#sec3dot6-microorganisms-08-00375}
-------------------------------------------

At the beginning of the 21^st^ century, *A. baumannii* attracted the attention of researchers due to its rapid spread and its resistance to most of the antibiotics used. In a surveillance study performed from 2001 to 2008 in 53 German intensive care units (ICUs), the resistance to imipenem increased from 1.1% in 2001 to 4.5% in 2008 \[[@B61-microorganisms-08-00375]\]. From 2002 to 2006, the rate of isolation of *A. baumannii* increased in university hospitals of six German federal states (Baden-Wuerttemberg, Hesse, Lower Saxony, Saxony, Schleswig--Holstein and Thuringia) from 2.1% in 2002 to 7.9% in 2006 \[[@B46-microorganisms-08-00375]\] and the proportion of MDR of *A. baumannii* isolates raised among inpatients \[[@B46-microorganisms-08-00375]\]. XDR strains resistant to all available antibiotics except colistin have been isolated from wound, skin and respiratory tract samples in an outbreak in 2003 \[[@B14-microorganisms-08-00375]\]. To overcome the resistance developed against broad-spectrum antibiotics tetracycline, tigecycline a new class of antibiotics derived from tetracycline has been implemented in 2006. Between 2004 and 2007, tigecycline had excellent activity against *A. baumannii* and other Gram-negative nosocomial bacteria \[[@B49-microorganisms-08-00375],[@B50-microorganisms-08-00375],[@B51-microorganisms-08-00375]\]. Until 2005 carbapenems remained the gold standard of therapy for severe *A. baumannii* infections and resistance to carbapenems remained low (0.3%) \[[@B54-microorganisms-08-00375]\]. In 2006, the first outbreak of carbapenem-resistant *A. baumannii* (CRAb), carrying the *bla*OXA-23-like gene, was reported in Germany. The strain was resistant to imipenem, meropenem, penicillins, cephalosporins, ciprofloxacin, gentamicin, tobramycin and tigecycline and was related to the pan-European *A. baumannii* clone II \[[@B16-microorganisms-08-00375]\]. Since then, carbapenemase-producing strains have been recovered from several outbreaks every year \[[@B26-microorganisms-08-00375],[@B27-microorganisms-08-00375],[@B30-microorganisms-08-00375],[@B33-microorganisms-08-00375],[@B62-microorganisms-08-00375]\]. According to the National Reference Laboratory for Gram-negative nosocomial pathogens at the Ruhr-University Bochum, CRAb was found in 96.3% of strains and *bla*OXA-23 was the most frequent carbapenemase in *A. baumannii* (81.1%) in 2011 \[[@B41-microorganisms-08-00375]\]. This high resistance rates can be explained by the practice that only non-susceptible strains are sent to the National Reference Laboratory for clarification. It is worth to mention that, the number of cases of carbapenem insensitive *Acinetobacter* infection or colonization was 794 in 2017 and 784 in 2018 \[[@B60-microorganisms-08-00375]\]. In contrast, the ARS data demonstrate that only 4% of *A. baumannii* ABC complex strains were not carbapenem sensitive in 2015 to 2018 (<https://ars.rki.de/Content/Database/ResistanceOverview.aspx>).

Susceptibility to tigecycline and colistin was reported in four and nineteen studies, respectively ([Table 3](#microorganisms-08-00375-t003){ref-type="table"}). Susceptibility to colistin and tigecycline remained unaffected until December 2013. At this time, the first reported pan drug-resistant (PDR)-CRAb strain was recovered from a patient at Goethe University hospital Frankfurt after a previous hospitalization in Greece. This strain was also resistant to colistin \[[@B19-microorganisms-08-00375]\]. Until 2018 colistin-resistant strains were detected three times in Germany. One was isolated from a human in 2013 in Frankfurt \[[@B19-microorganisms-08-00375]\], one from a dog in Giessen in 2011 \[[@B63-microorganisms-08-00375]\] and one from wastewater in 2017 \[[@B64-microorganisms-08-00375]\]. It has to be taken in consideration that most of the earlier colistin testing was performed by gradient tests for example, disc diffusion, E-test or with VITEK. EUCAST has revised the recommendation for colistin AST and microdilution technique is considered the only reliable method \[[@B65-microorganisms-08-00375]\]. Tigecycline resistant strains were reported five times: once in 2016 in Leverkusen \[[@B30-microorganisms-08-00375]\], once in 2014 from Frankfurt \[[@B19-microorganisms-08-00375]\], two times in 2010 from the university hospital Frankfurt \[[@B47-microorganisms-08-00375]\] and from the university hospital Rostock \[[@B15-microorganisms-08-00375]\] and once in 2009 with undetermined location \[[@B16-microorganisms-08-00375]\]. Colistin, tigecycline, aminoglycosides, fosfomycin, ceftazidime/avibactam and ceftolozan/tazobactam are often used antibiotics to treat 4MRGN *A. baumannii* infection in Germany \[[@B66-microorganisms-08-00375]\]. Information regarding the resistance patterns of *A. baumannii* are shown in [Table 3](#microorganisms-08-00375-t003){ref-type="table"}.

3.7. Resistance Genes in A. baumannii {#sec3dot7-microorganisms-08-00375}
-------------------------------------

Twenty-eight of the selected studies described AMR genes. As shown in [Table 3](#microorganisms-08-00375-t003){ref-type="table"}, the metallo-ß-lactamase was first described in studies published in 2004, 2005 and 2006 \[[@B14-microorganisms-08-00375],[@B52-microorganisms-08-00375],[@B53-microorganisms-08-00375]\]. The oxacillinase *blaOXA*-23-like, the intrinsic *bla*OXA-51-like, the New Delhi Metallo-ß-lactamases (*bla*NDM) and the *bla*OXA-58-like variant are the most dominant resistance genes that have been described in *A. baumannii* from Germany ([Table 3](#microorganisms-08-00375-t003){ref-type="table"}). The gene *blaOXA*-23-like, the intrinsic *bla*OXA-51-like and the *bla*OXA-58-like variants were found in a CRAb strain for the first time in an outbreak, which occurred at a German university medical center in 2006. However, the location of the sampling was ignored \[[@B16-microorganisms-08-00375]\]. Those three genes have been reported later on in sixteen, elven and seven studies, respectively. In 2011, the National Reference Laboratory for Gram-negative nosocomial pathogens at Ruhr-University Bochum found that the *bla*OXA-23 was the most frequent carbapenemase in *A. baumannii* \[[@B41-microorganisms-08-00375]\]. The first isolation of a *bla*NDM-1 strain was reported in 2007 in Frankfurt \[[@B47-microorganisms-08-00375]\] and then in ten other studies. Additionally, Guiana extended-spectrum β-lactamases (GES-11) \[[@B41-microorganisms-08-00375]\], Cefotaxime Hydrolyzing Capabilities (CTX-M) β-lactamases \[[@B28-microorganisms-08-00375]\], Temoneira (TEM) and Plasmid-Mediated Quinolone Resistance (PMQR) \[[@B35-microorganisms-08-00375]\], German imipenemase (GIM-1), VIP-2 and Verona integron-encoded-metallo-β-lactamase (VIM-2) \[[@B32-microorganisms-08-00375]\] and *bla*ADC-25-like \[[@B18-microorganisms-08-00375]\] have been described in *A. baumannii* ([Table 3](#microorganisms-08-00375-t003){ref-type="table"}). [Figure 3](#microorganisms-08-00375-f003){ref-type="fig"} represents the chronological emergence of resistance to carbapenems, colistin, tigecycline and quinolones antibiotics as well as the resistance genes according to time of sampling or time of reporting if the time of sampling is not available.

3.8. Clonality and Sequence Typing {#sec3dot8-microorganisms-08-00375}
----------------------------------

Cluster analysis based on Pulsed-field Gel Electrophoresis (PFGE) and rep-PCR typing identified five clonal lineages of *A. baumannii* in Germany, IC-2, IC-7, IC-1, IC-4 and IC-6. The international clone IC-2 is the most common clonal lineage widespread in Germany and was present in seven studies. Followed by IC-7 and IC-1, each was reported in two studies, while IC-4 and IC-6, each was identified only in one study. IC-2 was detected in five studies alone \[[@B16-microorganisms-08-00375],[@B19-microorganisms-08-00375],[@B27-microorganisms-08-00375],[@B33-microorganisms-08-00375],[@B42-microorganisms-08-00375]\] and in combination with IC-6 once \[[@B28-microorganisms-08-00375]\] and with IC-1, IC-7 and IC-4 in another study during the investigation of strains collected from different laboratories in the years 2005, 2007 and 2009 \[[@B39-microorganisms-08-00375]\]. Only six sequence types of *A. baumannii* have been reported in the reviewed articles. Multilocus sequence typing (MLST) revealed ST22 and ST53 types among 13 strains recovered from an outbreak of seven patients in Rostock \[[@B15-microorganisms-08-00375]\]. ST195 and ST218 were identified in an outbreak involving ten patients in Leverkusen \[[@B30-microorganisms-08-00375]\]. ST944/ST78 and ST348/ST2 were determined in three isolates recovered from two patients hospitalized in Bavaria and Hesse \[[@B28-microorganisms-08-00375]\].

3.9. The Risk Factors Associated with A. baumannii Infections {#sec3dot9-microorganisms-08-00375}
-------------------------------------------------------------

Investigation and outbreak studies, as well as case reports analyzed in this review, have reported multiple risk factors for the emergence and acquisition of *A. baumannii* infections. Firstly, travel, medical tourism or contact with health care systems abroad, as well as cross border transfer of patients from highly endemic countries into Germany, lead to the import and emerging presence of *A. baumannii* in the German hospitals. Between June and December 2015, 143 refugees have been admitted to the University hospital Frankfurt, Hesse. 60.8% were positive for MDR Gram-negative bacteria and CRAb strains harboring *bla*OXA-23 and OXA-24 genes were reported in 1.4% of clinical samples examined \[[@B27-microorganisms-08-00375]\]. *bla*OXA-23 and *bla*OXA-48, the most frequently reported resistance genes in Germany, were detected with high prevalence among Libyan war casualties admitted to the Northwest Medical Center (NMC) in Frankfurt/Main, Hesse between August 2016 and January 2017 \[[@B24-microorganisms-08-00375]\]. MDR *A. baumannii* was recovered from patients in German hospitals after previous hospitalization in Russia \[[@B28-microorganisms-08-00375],[@B34-microorganisms-08-00375]\], Thailand \[[@B30-microorganisms-08-00375]\], Serbia \[[@B42-microorganisms-08-00375],[@B47-microorganisms-08-00375]\], Poland \[[@B43-microorganisms-08-00375]\], China, the United Arabic Emirates and Croatia \[[@B37-microorganisms-08-00375]\], Greece and Italy \[[@B53-microorganisms-08-00375]\] and other Mediterranean countries \[[@B52-microorganisms-08-00375]\]. A patient was infected in Cameroon \[[@B14-microorganisms-08-00375]\]. First reports on PDR (pan-drug resistant) *A. baumannii* appeared in 2001 and an outbreak was reported in Spain in 2002 \[[@B67-microorganisms-08-00375]\]. Subsequently, the first isolation of a PDR strain in Germany belonging to the IC-2 cluster was done from the skin and rectal swab samples of a patient previously hospitalized in Greece \[[@B19-microorganisms-08-00375]\]. In contrast, a CRAb strain harboring *bla*OXA-23 was isolated from a hip joint infection in a patient with no history of traveling abroad at the University hospital Bonn \[[@B33-microorganisms-08-00375]\]. Between 2005 and 2009, 140 CRAb strains were isolated in 15 different medical centers in Germany, only 32% of these strains belonged to one of the known international clonal lineages \[[@B39-microorganisms-08-00375]\].

Secondly, during a (long-term) ICU stay, *A. baumannii* can be acquired via mechanical ventilation. An epidemic strain of *A. baumannii* was transferred from the index patient to other nine patients at the same hospital in Leverkusen, North Rhine-Westphalia within 16 days \[[@B30-microorganisms-08-00375]\]. Cross-transmission via the hands of health care workers from colonized or infected patients has been described in an epidemic setting in a German university medical center in Berlin \[[@B16-microorganisms-08-00375]\]. In one year, 44 individual patients acquired infection in a hospital in Cologne. *A. baumannii* was recovered from the washbasin and fixation bath \[[@B18-microorganisms-08-00375]\], from medical devices, infusion pumps and oxygen masks \[[@B15-microorganisms-08-00375],[@B16-microorganisms-08-00375]\]. An identical macrorestriction pattern (PFGE-type) was detected in isolates of two different hospitals in 2008 in North Rhine-Westphalia confirming that inter-hospital transmission is possible \[[@B26-microorganisms-08-00375]\]. Moreover, a prolonged hospital stay is frequently associated with exposure to antibiotics \[[@B68-microorganisms-08-00375]\]. *A. baumannii* can rapidly acquire resistance by mutation during antimicrobial therapy \[[@B44-microorganisms-08-00375]\]. Selective pressure due to preceding antimicrobial treatment was a significant factor in acquiring carbapenem-resistance in a study from Hamburg-Eppendorf, Hamburg \[[@B21-microorganisms-08-00375]\].

Finally, the environmental resilience of *A. baumannii* and environmental contamination facilitates the spread and dissemination of infection from colonized or infected patients. Examination of environmental samples during an outbreak revealed relevant dissemination of *A. baumannii* \[[@B18-microorganisms-08-00375]\]. *A. baumannii* was isolated from the patients' environment, patients' belongings and room equipment \[[@B15-microorganisms-08-00375],[@B16-microorganisms-08-00375]\]. *A. baumannii* can survive in the environment for a prolonged time and it can colonize non-human hosts for example, pet animals with ease \[[@B69-microorganisms-08-00375]\]. The occurrence of genotypically related clones I--III in animals and humans in Germany raises the concern about the possibility of a spillover of the organisms from humans to animals or *vice versa* \[[@B63-microorganisms-08-00375]\]. Strains harboring resistance genes coding for clinically relevant antibiotics can enter the clinical setting via food and community routes \[[@B70-microorganisms-08-00375],[@B71-microorganisms-08-00375]\]. Thus, humans can be colonized by *A. baumannii* through the food chain or from other environmental sources for example, wastewater, hatchery system and dust.

4. Discussion {#sec4-microorganisms-08-00375}
=============

*Acinetobacter baumannii* is one of the most threatening emerging environmental pathogens, causing particularly nosocomial infections in humans in Germany. The number of published studies concerning *A. baumannii* is dramatically increasing worldwide and also in Germany. This systematic review investigated the spatial and temporal distribution of *A. baumannii* in humans in Germany based on published data from 2000 to 2018. The pathogen was extensively studied in the last few years. This increase of interest reflects the increasing clinical impact and its ability to acquire resistance against the majority of antibiotics. *A. baumannii* MDR strains that is, strains with resistance to all β-lactams including carbapenems and production of β-lactamases of several types, were reported nationwide. A prominent number of published articles originates from North Rhine-Westphalia. This state is located in the West of Germany and has the highest population of German states. A considerable number of reports also describe the situation of Hesse, which is a central German state. The cities Cologne and Frankfurt-am-Main are centres of *A. baumannii* research and are home to tertiary care clinics and hospitals which treat a relatively high numbers of patients in ICUs. These hospitals also run large highly specialized treatment units that received patients from abroad \[[@B18-microorganisms-08-00375],[@B24-microorganisms-08-00375]\]. The obtained results are in harmony with the official data of the Robert Koch Institute (RKI) considering numbers of infection or colonization of carbapenem non-susceptible *Acinetobacter* spp. and incidence \[[@B60-microorganisms-08-00375]\]. The official data published by RKI were included to avoid loss of information, aware the shortcoming of these data that is, no differentiation between the different species was made and that numbers do not present the total number of infections in Germany, as only carbapenem non-susceptible strains have to be notified. Information published by the ARS project cover data for the whole *A. baumannii* complex group.

The identification of *A. baumannii* was mostly based on the VITEK-2 system, MALDI-TOF and PCR. The failure of the semi-automated VITEK-2 system to correctly identify *A. baumannii* and predict carbapenem susceptibility is well known \[[@B44-microorganisms-08-00375]\]. MALDI-TOF log score values \>2000 were accepted in some laboratories for species identification \[[@B72-microorganisms-08-00375]\]. However, evaluation of species-specific score cut-off values of clinical *A. baumannii* revealed that a score value \> 2.3 is the valid score value for species identification \[[@B73-microorganisms-08-00375]\]. Species misidentification and false AST may negatively influence clinical outcome. *A. baumannii* is part of the ACB complex and it is difficult to distinguish *A. baumannii* from other species phenotypically. A proper, accurate and reliable molecular identification of *A. baumannii* to species level is needed and a typing method with high discriminatory power is crucial \[[@B18-microorganisms-08-00375],[@B44-microorganisms-08-00375]\] for diagnosis, epidemiological trace back and vaccine production. Rates of colonization and infection with triple (3MRGN) and quadruple (4MRGN) *A. baumannii* are on the rise in Germany \[[@B17-microorganisms-08-00375],[@B29-microorganisms-08-00375],[@B36-microorganisms-08-00375]\]. However, this type of classification is specific for Germany only. Carbapenems are the gold standard to date for the treatment of severe infections with MDR strains. However, the appearance of CRAb poses new challenges for treatment strategies \[[@B66-microorganisms-08-00375]\]. Nevertheless, colistin and tigecycline are therapeutic options and showed efficacy in the treatment of MDR strains \[[@B15-microorganisms-08-00375],[@B25-microorganisms-08-00375],[@B37-microorganisms-08-00375],[@B51-microorganisms-08-00375]\]. The appearance of colistin and tigecycline resistant \[[@B47-microorganisms-08-00375]\] and colistin-resistant strains carrying the *mcr-*1 gene in non-human sources \[[@B64-microorganisms-08-00375]\] will result in limited effectiveness in the near future. Several methods have been used to detect colistin and tigecycline resistant strains. The lack of EUCAST and CLSI breakpoints for tigecycline hampers the detection of tigecycline resistance and is a big challenge for clinicians \[[@B74-microorganisms-08-00375]\]. Accordingly, the breakpoint for *Enterobacteriaceae* was recommended and used in different studies in the past \[[@B16-microorganisms-08-00375]\]. However, caution is needed during interpretation. *A. baumannii* is intrinsically resistant to fosfomycin \[[@B75-microorganisms-08-00375]\]. Only six articles were found discussing resistance to fosfomycin. The first fosfomycin resistant *A. baumannii* isolate was reported from an outbreak at the university hospital Tuebingen in 2004 \[[@B14-microorganisms-08-00375]\] and then MDR strains resistant to fosfomycin were reported again in 2010, 2011, 2014 and 2017 \[[@B19-microorganisms-08-00375],[@B25-microorganisms-08-00375],[@B43-microorganisms-08-00375],[@B44-microorganisms-08-00375]\]. According to the Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI-ICUs) project, that was initiated in Germany in 2000, the resistance rate of MRGN pathogens increased markedly from 2001 to 2015 \[[@B76-microorganisms-08-00375]\]. The increase in *A. baumannii* isolates with resistance to imipenem has been reported from 2005 onwards with a pronounced trend. The resistance rate has more than doubled over recent years and reach to 43% in 2015 \[[@B76-microorganisms-08-00375]\]. The antibiotic resistance surveillance (ARS) project revealed that, the level of resistance in *A. baumannii* isolates obtained from patients in ICUs is about three times that higher than of isolates obtained from patients in normal and outpatient settings. 7.6% of *A. baumannii* strains were carbapenem resistant in 2014 and 4% in 2017 and 2018. However, it has to be kept in mind that this information is not restricted to *A. baumannii* but include all of the *A. baumannii* complex group (<https://ars.rki.de/Content/Database/ResistanceOverview.aspx>).

The *bla*OXA-23, *bla*OXA-51-like and *blaOXA*-58-like, as well as *bla*NDM-1 were the resistance genes most often found in *A. baumannii* in the last ten years followed by *bla*GES-11, *bla*CTX-M and *bla*VIM. Since the first description of the *bla*OXA-23 in a clinical isolate of *A. baumannii* in Scotland in 1995 \[[@B77-microorganisms-08-00375]\], *A. baumannii* harboring the *bla*OXA-23 gene spread to hospitals worldwide and were also detected in companion animals, livestock, environment and ectoparasites \[[@B78-microorganisms-08-00375]\]. It has become the most frequent carbapenemase gene among *A. baumannii* in most countries. Transfer of resistance genes from bacteria of other genera is a predominant mechanism of acquiring resistance to carbapenems in *A. baumannii.* The *bla*NDM-1 was identified mainly in *E. coli* and *K. pneumoniae* and to a lower extent in *Pseudomonas* and *Acinetobacter.* The first occurrence of *A. baumannii* carrying *bla*NDM-1 in Germany dates bake to the year 2007 \[[@B47-microorganisms-08-00375],[@B48-microorganisms-08-00375]\]. Hence, current PCR protocols only identify resistance-coding genes but provide no in-depth information regarding the functions and mechanisms of resistance development or actual clinical resistance. Detection and characterization of AMR genes are gradually moving from PCR to high throughput identification via sequencing and *in-silico* detection utilizing several databases now. However, the use of next-generation sequencing (NGS) to investigate AMR in *A. baumannii* is still rare and has just begun to start in Germany.

This discriminatory power enables transmission-chain analysis, optimizes surveillance and promotes suitable containment measures. It also offers the traits to identify transmission dynamics \[[@B79-microorganisms-08-00375]\]. Molecular characterization of AMR in *A. baumannii* often has been performed by using conventional methods and very few studies utilizing the WGS technology have been performed \[[@B18-microorganisms-08-00375],[@B31-microorganisms-08-00375],[@B35-microorganisms-08-00375]\]. For outbreak investigation, PFGE has been considered the gold standard for a long time but it has been replaced by NGS technology due to its higher discriminatory properties. Most of the WGS based studies on *A. baumannii* were performed in outbreak settings and there is little data on WGS in the context of surveillance.

International travel of colonized patients, especially from countries with high prevalence for example, Mediterranean and Asian countries has resulted in and still resulting in the introduction and later spread of MDR *A. baumannii* to Europe and subsequently into Germany \[[@B53-microorganisms-08-00375]\]. Following a fatal outbreak of six patients with *A. baumannii* infection-related death at a tertiary care facility in the northwest United States, comparative genomics of strains showed a close relation to strains isolated from Germany in 2003 \[[@B80-microorganisms-08-00375]\]. Isolates from Germany were found to share the same rep-PCR pattern with isolates from Turkey and the USA \[[@B81-microorganisms-08-00375]\] and identical to those from isolates from the UK \[[@B82-microorganisms-08-00375]\]. Thus, cross border transmission of MDR *A. baumannii* or its resistance genes have to be considered and the colonization status of patients treated abroad should be handled with care to avoid the spread of this pathogen into countries with low incidence rates \[[@B53-microorganisms-08-00375]\]. WGS can be the tool of choice to assist public health officer and clinicians to contain spread and to initiate well timed start of treatment with the best medication.

5. Conclusions {#sec5-microorganisms-08-00375}
==============

In conclusion, the published knowledge on the existence and general distribution of *A. baumannii* in the German population is gradually increasing over time but is mainly based on regional studies, outbreak investigations and case reports. Only few countrywide studies have been done yet. Several aspects of resistance development remain cryptic. Large cities with tertiary care hospitals and vital tourism are hot spots for research and publication activity on *A. baumannii.* MDR strains harboring diverse resistance genes were found in most of the federal states. Five clonal lineages and six sequence types of *A. baumannii* have been identified within the last 18 years in Germany. *A. baumannii* is part of the ACB complex and it is difficult to distinguish it from other species. Due to clinical needs, its differentiation from other members of the ACB complex species, particularly the closely related *A. pittii* and *A. nosocomialis* is required. Accurate and safe diagnostics for species identification as well as the definition of breakpoints for all antibiotics used needs to be established. Several risk factors contributing to the spread and dissemination of infection have been identified for example, travelling, medical tourisms, long-term stay at ICUs and the environmental contamination. Dissemination and infection rates of MDR (particularly those known in Germany as 3MRGN-Ab and 4MRGN-Ab) are on the rise nationwide and need to be considered a threat to public health.

Due to the nature of the data reported to RKI they cannot differentiate between the different species causing infection or colonization. The ARS project shaves this limitation as it collects data on the *A. baumannii* complex following a holistic approach. The reported data published by the National Reference Laboratory and the RKI do not sum up the total number of infections or colonizations in Germany because only carbapenem non-susceptible *Acinetobacter* strains need to be reported to the NRL and RKI. The nationwide One-Health genomic surveillance of *A. baumannii* using NGS technology to understand the dynamics of resistance and mobile genetic elements (MGEs) has to be in the center of public efforts, now the NGS is afford and available. Especially pets, livestock, food and the environment are neglected reservoirs and isolates from theses niches need to be investigated to assess their impact on human health and economy. Thus, identification of novel and alternative strategies for treatment, collaboration between the veterinary and human health sectors and the increase of awareness in the public and in the risk group are fields identified to be improved.
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microorganisms-08-00375-t001_Table 1

###### 

Spatio-temporal distribution of studies on *A. baumannii* of human origin in Germany from 2000 to 2018.

  Ref                                  First Author                   Yr. of Report   Sampling Date                    Location of Sampling                                                               Study Population                Sample Type                                                                                                                                    No. Of Strains/Cases   Type of Study
  ------------------------------------ ------------------------------ --------------- -------------------------------- ---------------------------------------------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------
  \[[@B21-microorganisms-08-00375]\]   (Katchanov et al., 2018)       2018            Sep. 2015 till Aug. 2016         Hamburg-Eppendorf, Hamburg                                                         119 Individual patients         Pneumonia and bloodstream infection                                                                                                            18 patients            Retrospective analysis
  \[[@B18-microorganisms-08-00375]\]   (Wendel et al., 2018)          2018            Apr. 2017 till Mar. 2018         Cologne, North Rhine-Westphalia                                                    44 Individual patients          Rectal and nose/throat swabs, tracheal secretion and patients environment                                                                      43/48 isolates         Retrospective analysis
  \[[@B22-microorganisms-08-00375]\]   (Kerz et al., 2018)            2018            ND                               Mainz, Rhineland-Palatinate                                                        One patient                     Blood culture and CSF                                                                                                                          1 case                 Case report
  \[[@B23-microorganisms-08-00375]\]   (Papan et al., 2018)           2018            Feb. till Dec. 2015              Munich, Bavaria                                                                    29 Individual patients          Wound, skin abscess, burn, synovial and thoracic drainage                                                                                      1 isolate              Routine bacterial diagnosis
  \[[@B24-microorganisms-08-00375]\]   (Lohr et al., 2018)            2018            Aug. 2016 till Jan. 2017         NMC, Frankfurt/Main, Hesse                                                         67 Libyan war victims           Rectal, nasopharyngeal and inguinal swabs and wounds                                                                                           15 isolates            Prevalence and investigation
  \[[@B25-microorganisms-08-00375]\]   (Tafelski et al., 2017)        2017            ND                               Berlin, Berlin                                                                     1 patient                       Cranial wound                                                                                                                                  1 isolate              Case report
  \[[@B26-microorganisms-08-00375]\]   (Rieber et al., 2017)          2017            Feb. 2008 till Jan. 2012         North Rhine-Westphalia                                                             22/44 hospitals                 Respiratory tract, wound, urine, vascular, joint, catheter, blood, intraoperative tissue, pharyngeal swabs                                     79/1167 isolates       Investigation study
  \[[@B27-microorganisms-08-00375]\]   (Reinheimer et al., 2016)      2016            Jun. till Dec. 2015              UHF, Frankfurt/Main, Hesse                                                         143 refugee, 1489 residents     Rectal swabs                                                                                                                                   4 isolates             Investigation study
  \[[@B28-microorganisms-08-00375]\]   (Pfeifer et al., 2016)         2016            Jul. 2012 till Sep. 2013         Hospitals in Hesse and Bavaria                                                     2 Russian patients              Intraoperative wound swab                                                                                                                      3 isolates             Case report
  \[[@B29-microorganisms-08-00375]\]   (Huenges et al., 2016)         2016            ND                               Kiel, Schleswig-Holstein                                                           1 patient                       Skin swab and urine                                                                                                                            1 case                 Case report
  \[[@B30-microorganisms-08-00375]\]   (Molter et al., 2016)          2016            7 Dec. 2011 till 24 Jan. 2012    Leverkusen                                                                         Outbreak, 10 patients           Throat, groin, trachea                                                                                                                         10 cases               Outbreak investigation
  \[[@B31-microorganisms-08-00375]\]   (Willems et al., 2016)         2016            Oct. 2013 till Mar. 2014         Muenster, North Rhine-Westphalia                                                   2 ICUs at UH                    Skin, central intravenous catheter, respiratory samples                                                                                        32 isolates            Routine surveillance study
  \[[@B32-microorganisms-08-00375]\]   (Ghebremedhin et al., 2016)    2016            ND                               UH Bochum and Wuppertal, North Rhine-Westphalia                                    Strain collection               Culture isolates from laboratories                                                                                                             38 isolates            Diagnostic study
  \[[@B33-microorganisms-08-00375]\]   (Hischebeth et al., 2015)      2015            ND                               UH Bonn, North Rhine-Westphalia                                                    1 patient                       Hip joint infection                                                                                                                            1 isolate              Case report
  \[[@B34-microorganisms-08-00375]\]   (Dersch et al., 2015)          2015            ND                               Freiburg, Baden-Württemberg                                                        1 patient                       Catheter associated ventriculitis/CSF                                                                                                          1 isolate              Case report
  \[[@B35-microorganisms-08-00375]\]   (Leistner et al., 2015)        2015            Jan. 2012 till Dec. 2013         Berlin, Berlin                                                                     213 Libyan patients             Rectal and nasal swabs                                                                                                                         4 cases                Prevalence and investigation
  \[[@B36-microorganisms-08-00375]\]   (Hauri et al., 2015)           2015            Jan. 2012 till Sep. 2014         Hesse                                                                              Laboratories information        Notification cases                                                                                                                             185 complex            Data survey
  \[[@B17-microorganisms-08-00375]\]   (Siemers et al., 2014)         2014            24 Dec. 2012 till 16 Jan. 2013   Burn center in Halle (Saale), Saxony-Anhalt                                        Outbreak, 7 patients            Nasal and throat swabs, blood, skin and wounds                                                                                                 7 cases                Outbreak investigation
  \[[@B19-microorganisms-08-00375]\]   (Gottig et al., 2014)          2014            Dec. 2013                        Frankfurt, Hesse                                                                   1 patient                       Skin and rectal swab                                                                                                                           1 PDR strain           Case report
  \[[@B37-microorganisms-08-00375]\]   (Lahmer et al., 2014)          2014            ND                               Munich, Bavaria                                                                    Outbreak, 6 patients            Blood culture, bronchoalveolar lavage and ascites                                                                                              6 cases                Outbreak investigation
  \[[@B38-microorganisms-08-00375]\]   (Kleinkauf et al., 2014)       2014            Apr. 2012 till Mar. 2013         Frankfurt/Main, Hesse                                                              Health care facilities          Notification cases, mainly wound swabs                                                                                                         28 cases               Descriptive analysis of data
  \[[@B39-microorganisms-08-00375]\]   (Schleicher et al., 2013)      2013            2005, 2007 and 2009              ND                                                                                 15 Diagnostic laboratories      Respiratory tract, wound, intra-abdominal, blood culture                                                                                       140 isolates           Surveillance study
  \[[@B40-microorganisms-08-00375]\]   (Kaase, 2012a)                 2012            2011                             multi-centric study, NRL for MDRGNB, Bochum                                        Strain collection               Respiratory, wound, urine and blood culture                                                                                                    292 isolates           Surveillance study
  \[[@B41-microorganisms-08-00375]\]   (Kaase, 2012b)                 2012            2011                             Nationwide (16 States), NRL for MDRGNB, Bochum                                     Strain collection               ND                                                                                                                                             287 isolates           Surveillance study
  \[[@B42-microorganisms-08-00375]\]   (Pfeifer et al., 2011)         2011            2007                             ND                                                                                 1 patient                       ND                                                                                                                                             1 isolate 161/07       Investigation study
  \[[@B43-microorganisms-08-00375]\]   (Wagner et al., 2011)          2011            ND                               Leipzig, Saxony                                                                    1 patient                       Deep wound                                                                                                                                     1 isolate              Case report
  \[[@B44-microorganisms-08-00375]\]   (Higgins et al., 2010)         2010            ND                               Cologne UH, North Rhine-Westphalia                                                 1 patient                       Respiratory, blood and bedsore                                                                                                                 33 isolates            Case report
  \[[@B45-microorganisms-08-00375]\]   (Aivazova et al., 2010)        2010            ND                               LMU, Munich, Bavaria                                                               1 patient                       Vaginal smear                                                                                                                                  1 isolate              Case report
  \[[@B46-microorganisms-08-00375]\]   (Wadl et al., 2010)            2010            2002 till 2006                   Thuringia, Baden-Wuerttemberg, Hesse, Lower Saxony, Saxony, Schleswig-- Holstein   4 from 6 University hospitals   Respiratory, blood, urine, non-specific                                                                                                        1190 isolates          Retrospective and descriptive analysis of data
  \[[@B47-microorganisms-08-00375]\]   (Gottig et al., 2010)          2010            2007                             UHF, Frankfurt, Hesse                                                              1 patient                       Skin, tracheal secretion, vessels prosthesis and wound                                                                                         ND                     Case report
  \[[@B15-microorganisms-08-00375]\]   (Frickmann et al., 2010)       2010            ND                               UH Rostock, Mecklenburg-Vorpommern                                                 Outbreak, 7 patients            Medical devices, patient associated objectives, room equipment, urine, blood, testicular smear, lower respiratory, buccal swab, skin lesions   13 isolates            Outbreak investigation
  \[[@B48-microorganisms-08-00375]\]   (Pfeifer, 2010)                2010            2007                             South-Western Germany                                                              Hospital                        ND                                                                                                                                             Ten isolates           Case report
  \[[@B49-microorganisms-08-00375]\]   (Seifert and Dowzicky, 2009)   2009            2004--2007                       Throug out Germany                                                                 13 Centers                      ND                                                                                                                                             187 isolates           Evaluation of antibiotic activities
  \[[@B50-microorganisms-08-00375]\]   (Kresken et al., 2009)         2009            2007                             Throug out Germany                                                                 15 Centers                      Peritoneal cavity, respiratory, blood, urine and wound                                                                                         117 isolates           Evaluation of antibiotic activities
  \[[@B16-microorganisms-08-00375]\]   (Kohlenberg et al., 2009)      2009            18 Jun till 31 Aug. 2006         ND                                                                                 Outbreak, 39 patients           Wound, lower respiratory (one from each infusion pump, oxygen mask, hand of health care worker)                                                39 isolates            Outbreak investigation
  \[[@B51-microorganisms-08-00375]\]   (Rodloff et al., 2008)         2008            Jan. 2004 till Aug. 2006         Throug out Germany                                                                 7 Medical centers               Blood, wound, skin, urine, respiratory                                                                                                         86 isolates            Evaluation of antibiotic activities
  \[[@B52-microorganisms-08-00375]\]   (Weyrich et al., 2006)         2006            ND                               UH, Tuebingen, Baden-Württemberg                                                   1 patient                       Blood culture                                                                                                                                  1 case                 Case report
  \[[@B53-microorganisms-08-00375]\]   (Schulte et al., 2005)         2005            ND                               South-Western Germany                                                              2 patients                      Blood culture, excised tissue from fracture patella                                                                                            2 isolates             Case report
  \[[@B54-microorganisms-08-00375]\]   (Brauers et al., 2005)         2005            ND                               Throug out Germany + HU in Cologne, Freiburg, Leipzig                              13 Laboratories                 Blood culture, respiratory and urine                                                                                                           395 isolates           Evaluation of antibiotic activities
  \[[@B14-microorganisms-08-00375]\]   (Borgmann et al., 2004)        2004            Feb. until Mar. 2003             UH, Tuebingen, Baden-Württemberg                                                   Outbreak, 14 patients           Wound, skin, respiratory                                                                                                                       250 isolates           Outbreak investigation
  \[[@B55-microorganisms-08-00375]\]   (Higgins et al., 2004b)        2004            1991--1992                       Cologne, North Rhine-Westphalia                                                    2 Hospital outbreaks            Urine, blood culture                                                                                                                           34 cases               Outbreak investigation
  \[[@B56-microorganisms-08-00375]\]   (Frank et al., 2003)           2003            ND                               Throug out Germany                                                                 19 Laboratories                 Urinary, respiratory tract, wound, blood                                                                                                       51 isolates            Evaluation of antibiotic activities
  \[[@B57-microorganisms-08-00375]\]   (Andermahr et al., 2002)       2002            Jun. 1996 till Jun 2001          Cologne, North Rhine-Westphalia                                                    266 patients                    Tracheal aspirate                                                                                                                              41 cases               Routine bacterial diagnosis
  \[[@B58-microorganisms-08-00375]\]   (Heinemann et al., 2000)       2000            Jul. 1990 till Dec. 1998         Cologne, North Rhine-Westphalia                                                    Outbreaks and sporadic cases    Blood, urine, wound, tracheal secretion                                                                                                        47 isolates            Evaluation of antibiotic activities

ND: not determined, MDR: Multidrug-resistant, MIC: minimum inhibitory concentrations, UH: university hospital.

microorganisms-08-00375-t002_Table 2

###### 

Number of the nosocomial outbreaks of carbapenem-non-susceptible *Acinetobacter* spp. in Germany based on official data published by the Robert Koch Institute (RKI) (2010--2018).

  Year of Report   No. of Outbreaks   No. of Cases   No. of Deaths   No. of Infection   Incidence
  ---------------- ------------------ -------------- --------------- ------------------ -----------
  **2018**         5                  18             5               784                0.9
  **2017**         7                  41             11              794                1.0
  **2016**         10                 38             8               \-                 \-
  **2015**         8                  56             27              \-                 \-
  **2014**         6                  29             1               \-                 \-
  **2013**         14                 67             4               \-                 \-
  **2012**         13                 86             9               \-                 \-
  **2011**         \-                 \-             \-              \-                 \-
  **2010**         \-                 \-             \-              \-                 \-

microorganisms-08-00375-t003_Table 3

###### 

Temporal distribution of resistance profiles of *A. baumannii* strains from Germany based on studies published from 2000 to 2018.

  No.                                  References                     Sampling Date                       Resistant Antibiotics                                                                                                                                                                                                                                                                                             Susceptible Antibiotics                                                                                                                             Resistance Genes                                                                                                                                                        ST/IC
  ------------------------------------ ------------------------------ ----------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  \[[@B21-microorganisms-08-00375]\]   (Katchanov et al., 2018)       Sep. 2015 till Aug. 2016            MDR, carbapenem-resistant                                                                                                                                                                                                                                                                                         Colistin in all tested ten isolates                                                                                                                 Ten isolates carry *bla*OXA-23                                                                                                                                          ND
  \[[@B18-microorganisms-08-00375]\]   (Wendel et al., 2018)          Apr. 2017 till Mar. 2018            Two strains were carbapenem-resistant                                                                                                                                                                                                                                                                             Carbapenem-2.1. Historical glance on the situation in human                                                                                         Cephalosporinase-encoding *bla*ADC-25-like, *bla*OXA-106-like, *bla*OXA-51                                                                                              ND
  \[[@B22-microorganisms-08-00375]\]   (Kerz et al., 2018)            ND                                  Carbapenemase-producing (Meropenem \> 32 mg/L)                                                                                                                                                                                                                                                                    Colistin \< 1 mg/L                                                                                                                                  *bla*OXA-23 and *bla*NDM-1                                                                                                                                              ND
  \[[@B23-microorganisms-08-00375]\]   (Papan et al., 2018)           Feb. till Dec. 2015                 One strain was carbapenem-resistant                                                                                                                                                                                                                                                                               ND                                                                                                                                                  *bla*OXA-24/40                                                                                                                                                          ND
  \[[@B24-microorganisms-08-00375]\]   (Lohr et al., 2018)            Aug. 2016 till Jan. 2017            Carbapenemase-producing                                                                                                                                                                                                                                                                                           ND                                                                                                                                                  *bla*OXA-23 (*n* = 9), *bla*NDM (*n* = 2), *bla*NDM+OXA-51-ISAbaI (*n* = 4), TEM and PMQR gene *aac*(6\`)-Ib-cr                                                         ND
  \[[@B25-microorganisms-08-00375]\]   (Tafelski et al., 2017)        ND                                  MDR, imipenem, meropenem ceftriaxone, amikacin, cotrimoxazole, fosfomycin, ciprofloxacin, levofloxacin.                                                                                                                                                                                                           Colistin \< 0.5 mg/L and tobramycin                                                                                                                 ND                                                                                                                                                                      ND
  \[[@B26-microorganisms-08-00375]\]   (Rieber et al., 2017)          Feb. 2008 till Jan. 2012            ESBL, Carbapenem-resistant, ciprofloxacin and gentamicin                                                                                                                                                                                                                                                          Polymyxin B                                                                                                                                         *bla*OXA-23 (*n* = 66), *bla*OXA-80 (*n* = 1), *bla*OXA-82 (*n* = 3), TEM-like (n = 62), GES-11 (*n* = 1), PER-1 (*n* = 1); *bla*OXA-51-like (OXA-51, OXA-66, OXA-69)   ND
  \[[@B27-microorganisms-08-00375]\]   (Reinheimer et al., 2016)      Jun. till Dec. 2015                 Three strains were carbapenem-resistant from refugee and one from residents                                                                                                                                                                                                                                       ND                                                                                                                                                  *bla*OXA-23 and *bla*OXA-24 in refugee and *bla*OXA-51 in resident                                                                                                      IC-2
  \[[@B28-microorganisms-08-00375]\]   (Pfeifer et al., 2016)         Jul. 2012 till Sep. 2013            Penicillin/inhibitor combinations, cefepime, imipenem, meropenem, aminoglycosides (gentamicin, tobramycin and amikacin), fluoroquinolones (ciprofloxacin) and sulfamethoxazole/trimethoprim.                                                                                                                      Colistin                                                                                                                                            *bla*OXA-40/24 related *bla*OXA-72, *bla*OXA-66, *bla*OXA-90, ESBL-*bla*CTX-M-2-like genes and *bla*CTX-M-115                                                           IC-2, IC-6, ST944/ST78 ST348/ST2
  \[[@B29-microorganisms-08-00375]\]   (Huenges et al., 2016)         ND                                  4MRGN-ab, intermediate to carbapenems                                                                                                                                                                                                                                                                             Colistin                                                                                                                                            ND                                                                                                                                                                      ND
  \[[@B30-microorganisms-08-00375]\]   (Molter et al., 2016)          7 Dec. 2011 till 24 Jan. 2012       Carbapenems, ciprofloxacin and tobramycin; variable to tigecycline (≤0.5 to 4 mg/L) and amikacin (4 to ≥ 64 mg/L).                                                                                                                                                                                                Colistin (MIC 0.5--1 mg/L)                                                                                                                          *bla*OXA-51-like and *bla*OXA-23-like                                                                                                                                   IC-2, ST195 and ST218
  \[[@B31-microorganisms-08-00375]\]   (Willems et al., 2016)         Oct. 2013 till Mar. 2014            MDR, piperacillin, 3rd/4th generation cephalosporins and fluoroquinolones                                                                                                                                                                                                                                         Carbapenems, imipenem and meropenem                                                                                                                 ND                                                                                                                                                                      ND
  \[[@B32-microorganisms-08-00375]\]   (Ghebremedhin et al., 2016)    ND                                  Carbapenemase-producing                                                                                                                                                                                                                                                                                           ND                                                                                                                                                  *bla*OXA-23, *bla*OXA-40, *bla*OXA-58, *bla*OXA-72, *bla*OXA-164, *bla*NDM-1, GIM-1, VIP-2 and VIM-2                                                                    ND
  \[[@B33-microorganisms-08-00375]\]   (Hischebeth et al., 2015)      ND                                  Carbapenemase-producing, meropenem (MIC ≥ 32 mg/L) and imipenem (MIC ≥ 32 mg/L), tobramycin (MIC ≥ 16 mg/L) gentamicin (MIC ≥ 16 mg/L)                                                                                                                                                                            Colistin only (MIC ≤ 0.5 mg/L)                                                                                                                      *bla*OXA-23-like and *bla*OXA-51-like.                                                                                                                                  IC-2
  \[[@B34-microorganisms-08-00375]\]   (Dersch et al., 2015)          ND                                  MDR                                                                                                                                                                                                                                                                                                               Colistin                                                                                                                                            ND                                                                                                                                                                      ND
  \[[@B35-microorganisms-08-00375]\]   (Leistner et al., 2015)        Jan. 2012 till Dec. 2013            ESBL, Carbapenem-resistant, Imipenem and Meropenem (MIC ≥ 16 mg/L), Ertapenem (MIC ≥ 32 mg/L).                                                                                                                                                                                                                    ND                                                                                                                                                  *bla*OXA-23, TEM-1, GES-11; PMQR genes (*aac*(6´)1b-cr)                                                                                                                 ND
  \[[@B36-microorganisms-08-00375]\]   (Hauri et al., 2015)           Jan. 2012 till Sep. 2014            4MRGN, acylureidopenicillins, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolone.                                                                                                                                                                                                                    ND                                                                                                                                                  *bla*OXA-23 and *bla*NDM                                                                                                                                                ND
  \[[@B17-microorganisms-08-00375]\]   (Siemers et al., 2014)         24 Dec. till 2012 to 16 Jan. 2013   4MRGN, acylureidopenicillins, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolone.                                                                                                                                                                                                                    Colistin                                                                                                                                            *bla*OXA-58                                                                                                                                                             ND
  \[[@B19-microorganisms-08-00375]\]   (Gottig et al., 2014)          Dec. 2013                           PDR, penicillins/β-lactamase inhibitors, extended-spectrum cephalosporins, carbapenems, tetracyclines, fluoroquinolones, aminoglycosides, folate pathway inhibitors and polymyxins, including colistin (MIC \> 128 mg/L) and tigecycline (MIC \> 8 mg/L), chloramphenicol and fosfomycin                          Intermediately susceptible to minocycline (MIC 8 mg/L)                                                                                              *Bla*OXA-23, *bla*OXA-51-like (*bla*OXA-61)                                                                                                                             IC-2
  \[[@B37-microorganisms-08-00375]\]   (Lahmer et al., 2014)          ND                                  MDR, Carbapenem-resistant                                                                                                                                                                                                                                                                                         Tigecycline and colistin                                                                                                                            ND                                                                                                                                                                      ND
  \[[@B38-microorganisms-08-00375]\]   (Kleinkauf et al., 2014)       Apr. 2012 till Mar. 2013            Carbapenem-resistant                                                                                                                                                                                                                                                                                                                                                                                                                                                  *bla*OXA-23-like and *bla*NDM-1                                                                                                                                         ND
  \[[@B39-microorganisms-08-00375]\]   (Schleicher et al., 2013)      2005, 2007 and 2009                 Non-susceptible to carbapenem and imipenem                                                                                                                                                                                                                                                                        ND                                                                                                                                                  *bla*OXA-58-like and *bla*OXA-23-like.                                                                                                                                  IC-2, IC-1, IC-4, IC-7
  \[[@B40-microorganisms-08-00375]\]   (Kaase, 2012a)                 2011                                Carbapenem-resistant, imipenem and meropenem,                                                                                                                                                                                                                                                                     ND                                                                                                                                                  *bla*OXA-23, *bla*OXA-72, *bla*OXA-58, *bla*OXA-164, NDM-1, ISAba1 insertion *bla*OXA-51 and GES-11                                                                     ND
  \[[@B41-microorganisms-08-00375]\]   (Kaase, 2012b)                 2011                                Carbapenem-resistant, imipenem and meropenem,                                                                                                                                                                                                                                                                     ND                                                                                                                                                  *bla*OXA-23, b*la*OXA-72, *bla*OXA-58, *bla*OXA-164, NDM-1, ISAba1 insertion *bla*OXA-51 and GES-11                                                                     ND
  \[[@B42-microorganisms-08-00375]\]   (Pfeifer et al., 2011)         2007                                MDR, imipenem and meropenem, ertapenem (MIC \>32 mg/L), tigecycline (MIC1 mg/L)                                                                                                                                                                                                                                   Colistin (MIC 0.38 mg/L)                                                                                                                            *bla*NDM-1 and *bla*OXA-64                                                                                                                                              IC-7
  \[[@B43-microorganisms-08-00375]\]   (Wagner et al., 2011)          ND                                  MDR, ampicillin + sulbactam, piperacillin + tazobactam, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, aztreonam, ertapenem, amikacin, fosfomycin, levofloxacin, ciprofloxacin and moxifloxacin.                                                                                                               Imipenem and tobramycin                                                                                                                             ND                                                                                                                                                                      ND
  \[[@B44-microorganisms-08-00375]\]   (Higgins et al., 2010)         ND                                  Cefepime, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, moxifloxacin, fosfomycin, gentamicin, piperacillin, piperacillin-tazobactam and ampicillin-sulbactam, imipenem, meropenem. Amikacin variable (MIC ≤ 2 and ≥ 32 mg/L), tigecycline variable (MIC 2 and ≥ 8 µg/mL).                                    Colistin (MIC ≤1 µg/mL) and tobramycin (MIC ≤ 1 µg/mL)                                                                                              *bla*OXA-51-like (*bla*OXA-69), *bla*OXA-58-like variant (novel *bla*OXA-164 and *bla*OXA-58). *ade*B, *ade*J, novel *ade*R mutation                                    IC-1
  \[[@B45-microorganisms-08-00375]\]   (Aivazova et al., 2010)        ND                                  ND                                                                                                                                                                                                                                                                                                                Meropenem                                                                                                                                           ND                                                                                                                                                                      ND
  \[[@B46-microorganisms-08-00375]\]   (Wadl et al., 2010)            2002 till 2006                      66 are MDR, beta-lactams (piperacillin/ tazobactam), fluoroquinolones (ciprofloxacin, levofloxacin), cephalosporins (ceftazidime, cefepime), Aminoglycosides (tobramycin, gentamicin) and trimethoprim/ sulphamethoxazole combination cotrimoxazole.                                                              Lowest resistance in carbapenems (meropenem, imipenem) and beta-lactams (ampicillin/sulbactam).                                                     ND                                                                                                                                                                      ND
  \[[@B47-microorganisms-08-00375]\]   (Gottig et al., 2010)          2007                                Carbapenems, fluoroquinolones, aminoglycosides, tigecycline, aztreonam,                                                                                                                                                                                                                                           Colistin (MIC ≤ 1 µg/mL)                                                                                                                            *bla*NDM-1                                                                                                                                                              ND
  \[[@B15-microorganisms-08-00375]\]   (Frickmann et al., 2010)       ND                                  MDR (ampicillin-sulbactam, piperacillin-tazobactam, cefuroxime, cefotaxime, cefpodoxime, ceftazidime, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamycin, tobramycin, tetracycline, trimethoprim-sulfamethoxazole, tigecycline, doripenem, cefepime, ertapenem, moxifloxacin, fosfomycin, aztreonam).   Colistin                                                                                                                                            ND                                                                                                                                                                      ST22, ST53
  \[[@B48-microorganisms-08-00375]\]   (Pfeifer, 2010)                2007                                MDR, carbapenems                                                                                                                                                                                                                                                                                                  Colistin (MIC 0.25 µg/mL)                                                                                                                           *bla*NDM-1                                                                                                                                                              ND
  \[[@B49-microorganisms-08-00375]\]   (Seifert and Dowzicky, 2009)   2004--2007                          Ampicillin and amoxicillin/clavulanic acid (MIC ≥ 64 µg/mL), ceftriaxone (MIC ≥ 128 µg/mL) and cefepime (MIC 32 µg/mL)                                                                                                                                                                                            Tigecycline, amikacin and minocycline (MIC ≤1 µg/mL), imipenem, meropenem, levofloxacin,                                                            ND                                                                                                                                                                      ND
  \[[@B50-microorganisms-08-00375]\]   (Kresken et al., 2009)         2007                                Imipenem (11.1%), ciprofloxacin (27.4%), gentamycin (22.2%)                                                                                                                                                                                                                                                       Tigecycline (MIC ≤ 0.25/1 µg/mL)                                                                                                                    ND                                                                                                                                                                      ND
  \[[@B16-microorganisms-08-00375]\]   (Kohlenberg et al., 2009)      18 Jun till 31 Aug. 2006            Carbapenem-resistant, penicillins, cephalosporins, ciprofloxacin, gentamicin, tobramycin, tigecycline (4 mg/L), imipenem and meropenem (MIC ≥ 32 mg/L)                                                                                                                                                            Colistin (MIC ≤ 0.5 mg/L) and amikacin (MIC 4--8 mg/L). Two isolates susceptible to imipenem                                                        *bla*OXA-23-like, *bla*OXA-58-like intrinsic *bla*OXA-51                                                                                                                IC-2
  \[[@B51-microorganisms-08-00375]\]   (Rodloff et al., 2008)         Jan. 2004 till Aug. 2006            ND                                                                                                                                                                                                                                                                                                                Tigecycline (MIC ≤ 1 mg/L), \>80% for amikacin, cefepime, ceftazidime, imipenem (MIC 1 mg/L), levofloxacin, minocycline, piperacillin-tazobactam.   ND                                                                                                                                                                      ND
  \[[@B52-microorganisms-08-00375]\]   (Weyrich et al., 2006)         ND                                  MDR, penicillins, cephalosporins, aminoglycosides, fluoroquinolones, rifampicin, tetracyclines, oxazolidinones, macrolides and carbapenems (imipenem and imipenem/EDTA                                                                                                                                            Colistin                                                                                                                                            Metallo-ß-lactamase                                                                                                                                                     ND
  \[[@B53-microorganisms-08-00375]\]   (Schulte et al., 2005)         ND                                  Carbapenems, meropenem, penicillins, cephalosporins, aminoglycosides, quinolones                                                                                                                                                                                                                                  ND                                                                                                                                                  Metallo-ß-lactamase                                                                                                                                                     ND
  \[[@B54-microorganisms-08-00375]\]   (Brauers et al., 2005)         ND                                  MIC ≥ 64 mg/L in amoxicillin-clavulanate combinations, piperacillin-tazobactam and cefotaxime                                                                                                                                                                                                                     Ampicillin-sulbactam and piperacillin-sulbactam (MIC ≤ 0.06 mg/L), meropenem (MIC ≤ 1 mg/L)                                                         ND                                                                                                                                                                      ND
  \[[@B14-microorganisms-08-00375]\]   (Borgmann et al., 2004)        Feb. until Mar. 2003                MDR, gentamicin, aztreonam, piperacillin, piperacillin/ tazobactam, cefuroxime, cefotaxime, ceftazidime, cefepime, meropenem, tetracycline, levofloxacin, ciprofloxacin and fosfomycin                                                                                                                            Tobramycin, amikacin and colistin                                                                                                                   Metallo-ß-lactamase                                                                                                                                                     ND
  \[[@B55-microorganisms-08-00375]\]   (Higgins et al., 2004b)        1991--1992                          Ciprofloxacin, ofloxacin, meropenem, netilmicin, tetracycline, tobramycin, clarithromycin                                                                                                                                                                                                                         ND                                                                                                                                                  *gyr*A and *par*C mutation, up-regulation of *ade*B gene                                                                                                                ND
  \[[@B56-microorganisms-08-00375]\]   (Frank et al., 2003)           ND                                  ND                                                                                                                                                                                                                                                                                                                Piperacillin-sulbactam                                                                                                                              ND                                                                                                                                                                      ND
  \[[@B57-microorganisms-08-00375]\]   (Andermahr et al., 2002)       Jun. 1996 till Jun 2001             ND                                                                                                                                                                                                                                                                                                                ND                                                                                                                                                  ND                                                                                                                                                                      ND
  \[[@B58-microorganisms-08-00375]\]   (Heinemann et al., 2000)       Jul. 1990 till Dec. 1998            Novel quinolones superior to ciprofloxacin                                                                                                                                                                                                                                                                        Clinafloxacin most active                                                                                                                           ND                                                                                                                                                                      ND

ND: not determined, MDR: Multidrug-resistant, MIC: minimum inhibitory concentrations, ST/IC: sequence type and international clone.
